Streetbeat News

Revenues

GILT

Gilat Satellite Networks Ltd. (GILT) has received over $3M in orders from a leading IFC Service Provider to expand its In-Flight Connectivity capabilities, primarily for Gilat's Taurus Aero modems.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 11:21 am

TECH

Bio-Techne Corporation announced that its division, Advanced Cell Diagnostics, has surpassed 10,000 peer-reviewed publications citing its RNAscope ISH technology. Over half of these publications were in the last 3 years, indicating growing global customer awareness and market adoption in spatial biology.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 11:11 am

EYEN

Eyenovia has begun exploring strategic alternatives to enhance shareholder value, focusing on the development of MicroPine for pediatric progressive myopia, a potential multi-billion dollar product. The company aims to reduce operating expenses while leveraging its two FDA-approved products for value generation.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 11:02 am

IHT

InnSuites Hospitality Trust (IHT) expects limited new hotel supply in its markets for fiscal year 2025, leading to anticipated revenue growth and improved operating margins, as detailed in their 10K report.

Portfolio Pulse from Charles Gross

April 08, 2024 | 10:58 am

NUTX

Nutex Health Inc. (NASDAQ:NUTX) has announced the opening of Green Bay ER & Hospital in Bellevue, Wisconsin. This new facility is part of Nutex Health's integrated healthcare delivery system, which includes 21 micro hospitals across 9 states. The Green Bay ER & Hospital offers 24/7 concierge-level care, featuring eight ER beds, six inpatient beds, a procedure room, and in-house pharmacy, laboratory, and imaging services. The opening follows a successful open house event attended by over 200 community members.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 9:32 am

LEGN

Legend Biotech Corporation (NASDAQ:LEGN) announced FDA approval of CARVYKTI for second-line treatment of multiple myeloma, making it the first and only BCMA-targeted CAR-T cell therapy for this indication. The approval is based on the CARTITUDE-4 study showing significant improvement in progression-free survival compared to standard treatments. This marks a potential paradigm shift in multiple myeloma treatment, offering a personalized immunotherapy option earlier in the treatment regimen. The safety profile of CARVYKTI includes several warnings, and the company has expanded production capacity to meet demand.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:42 am

TEVA

Teva Pharmaceuticals presented new pharmacokinetic modeling data for UZEDY, an extended-release injectable suspension for schizophrenia, at SIRS 2024. The data offers insights into dosing conversions for switching from a long-acting injectable formulation of risperidone. Additional data from the Phase 3 RISE trial reinforces UZEDY's efficacy and safety. The ADVANCE study will provide real-world findings on long-acting injectable utilization from various stakeholders.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:14 am

UMC

United Microelectronics Corporation (UMC) reported a 2.70% year-over-year increase in March 2024 sales, reaching NT$18.2M. The first quarter sales also saw a slight rise of 0.78% compared to the same period in 2023.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:05 am

AMRN

New analyses of the REDUCE-IT study by Amarin demonstrate that its drug VASCEPA/VAZKEPA benefits high-risk cardiovascular disease patient subgroups. This could potentially enhance the drug's market position and appeal to a broader patient base.

Portfolio Pulse from Benzinga Newsdesk

April 08, 2024 | 7:04 am

TSLA

Tesla Inc. has deployed its Full Self-Driving (FSD) software on approximately 2 million vehicles in the U.S. The software, part of Tesla's advanced driver assistance systems, has reached a milestone of one billion miles driven. CEO Elon Musk highlighted the importance of vehicle autonomy to Tesla's market value and mentioned the potential of licensing FSD to other automakers, despite no current agreements. The company aims to enhance FSD adoption with initiatives like a 30-day free trial.

Portfolio Pulse from Anan Ashraf

April 08, 2024 | 6:52 am